首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1747089

日本生物晶片市场规模、份额、趋势及预测（按产品类型、製造技术、分析方法、应用、最终用户和地区），2025 年至 2033 年

Japan Biochips Market Size, Share, Trends and Forecast by Product Type, Fabrication Technique, Analysis Method, Application, End User, and Region, 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 118 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2024年，日本生物晶片市场规模达223亿美元。展望未来， IMARC Group预测，到2033年，市场规模将达到760亿美元，2025年至2033年的复合年增长率为13.02%。各种需要快速诊断的慢性疾病发生率不断上升，奈米技术和微晶片的进步，以及政府为改善医疗基础设施而不断增加的投资和实施的优惠措施，都是刺激日本市场成长的一些因素。

生物晶片体积小巧，易于操作，可提高侦测吞吐量和速度。它们被视为能够同时进行数百个生化反应的微型实验室。正因如此，它们已成为基因体学、蛋白质体学、药物研发和诊断等领域的重要工具。随着日本癌症、心血管疾病和糖尿病等慢性疾病的发生率不断上升，对先进诊断解决方案的需求也日益迫切。生物晶片能够透过基因组学和蛋白质组学分析实现疾病的早期发现，从而及时干预并改善患者预后。日本人口老化进一步加剧了对高效诊断工具的需求，因为老年人更容易患上慢性疾病。生物晶片提供了一种非侵入性、高精度的疾病筛检方法，在更注重预防的医疗保健系统中具有广泛的应用。

日本高度重视基因组学研究，并对精准医疗日益增长的兴趣是推动日本市场成长的关键因素。生物晶片在基因检测、生物标记发现和药物基因组学中的应用正在迅速扩展，从而能够根据个人基因图谱量身定制个人化治疗方案。这符合日本的医疗保健策略，该策略优先整合先进技术以加强患者护理。政府对相关措施的支持进一步加速了生物晶片在医学研究和临床应用的应用。这些进步不仅改善了医疗保健效果，也为市场参与者创造了巨大的机会。

日本生物晶片市场趋势：

慢性病的流行和先进诊断的需求

日本采用生物晶片技术的主要动力源自于日益沉重的慢性疾病负担，例如癌症、糖尿病和心血管疾病。日本人口老化问题日益严重，超过一半的人口年龄在65岁以上。因此，对用于治疗与年龄相关的疾病的高精度诊断解决方案的需求日益增长，显着影响了这一趋势。生物晶片，例如DNA微阵列和蛋白质晶片，有助于检测生物标记，从而实现疾病的早期诊断，从而提高准确性和效率。近期发布的产品重点在于生物晶片在诊断上的应用。最近的市场统计数据显示，到2024年，诊断应用将占据日本生物晶片整体市场份额的很大一部分。这一趋势的上升是由于医疗保健系统正将重点转向预防保健和精准医疗。生物晶片灵敏度高、速度快且经济高效。诊断工作流程离不开这些工具，这进一步巩固了它们在应对日本医疗保健挑战中的作用。根据IMARC Group的数据，日本精准医疗市场预计在 2024 年至 2032 年期间的复合年增长率为 4.95%。

技术进步和小型化

日本是全球创新和技术进步的领导者，因此市场受其推动。持续的研究和开发 (R&D) 工作确保设计出更小、更有效率、更具成本效益的生物晶片，从而倍增其使用率。在微型化技术中，奈米技术和微流体技术开闢了晶片实验室 (LOC) 系统，将多种实验室功能整合到单一微晶片中。这些发展可以轻鬆用于即时检验、环境监测甚至穿戴式医疗设备。另一个革命性趋势是将人工智慧与生物晶片结合。人工智慧演算法与生物晶片结合，具有先进的资料分析能力，可以更快、更准确地解释生物资料。根据IMARC Group的数据，到 2033 年，日本人工智慧市场规模预计将达到 87.77 亿美元。

强大的研发支持和有利的政府倡议

日本政府为支持生物晶片发展提供的资金、税收优惠政策以及公私合作模式，都确保了该国对生物晶片的支持。强有力的支持使日本在生物技术研究和生物晶片创新方面充满活力。政府已设定了精准医疗和先进诊断技术的发展目标，生物晶片将应用于这些领域。 2024年，日本政府将投资建置绿色医疗体系。这项重大倡议表明，日本决心应对气候变迁对健康的影响，并将确保建立可持续且富有韧性的医疗体系。这进一步促进了高效的晶片开发。私部门的参与者也积极投资研发。一些公司宣布了与大学合作开发用于神经系统疾病研究的生物晶片平台的策略，利用人工智慧解码复杂的蛋白质组学资料。这些合作凸显了学术界、产业界和政府在生物晶片技术开发上的紧密互动。凭藉强大的研究环境和政府推动创新的倡议，日本已成为吸引国内外利害关係人的枢纽。

The Japan biochips market size was valued at USD 22.3 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 76.0 Billion by 2033, exhibiting a CAGR of 13.02% from 2025-2033. The increasing occurrence of various chronic diseases requiring rapid diagnosis, advancements in nanotechnology and microchips, and rising investments and implementation of favorable governmental initiatives to improve healthcare infrastructure are some of the factors stimulating the market growth in Japan.

Biochips, being small in size, can easily be used to achieve increased throughput and speed in conducting tests. They are considered miniaturized laboratories capable of performing hundreds of simultaneous biochemical reactions. Owing to this, they have become essential tools in fields such as genomics, proteomics, drug discovery, and diagnostics. With the increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and diabetes in Japan, the need for advanced diagnostic solutions has become urgent. Biochips enable early detection of diseases through genomic and proteomic analysis, thereby allowing timely intervention and better patient outcomes. The aging population in Japan further aggravates the demand for efficient diagnostic tools, as the elderly are more susceptible to chronic diseases. Biochips give a non-invasive highly accurate means of disease screening that finds much applicability in a system of health care that focuses more on prevention.

Japan's strong emphasis on genomics research and the growing interest in precision medicine are key factors propelling the market growth in Japan. The application of biochips in genetic testing, biomarker discovery, and pharmacogenomics is expanding rapidly, enabling personalized treatment plans that are customized as per individual genetic profiles. This aligns with Japan's healthcare strategy, which prioritizes the integration of advanced technologies to enhance patient care. The government's support for initiatives further accelerates the adoption of biochips in medical research and clinical applications. These advancements are not only improving healthcare outcomes but also creating significant opportunities for market players.

Japan Biochips Market Trends:

Prevalence of Chronic Diseases and Need for Advanced Diagnostics

The major impetus behind adopting biochip technology in Japan arises from the increasingly burdened chronic diseases like cancer, diabetes, and cardiovascular disorders. Aging population is predominant in Japan as more than half of its population consists of individuals above 65 years. Hence, the growing demand for highly sophisticated diagnostic solutions for addressing age-related illnesses has significantly influenced this trend. Biochips, such as DNA microarrays and protein chips, facilitate the detection of biomarkers for the early diagnosis of diseases. This results in increased accuracy and efficiency. Recent product releases focus on the utility of biochips in diagnostics. Recent market statistics reveal that diagnostic applications formed a significant share of the overall biochip market share in Japan in 2024. This is on the rise because health care systems are shifting their focus towards preventive care and precision medicine. Biochips are highly sensitive, speedy, and cost-effective. The diagnostic workflow cannot do without these tools, further cementing their role in addressing Japan's healthcare challenges. According to the IMARC Group, the Japan's precision medicine market is expected to grow at a CAGR of 4.95% during 2024-2032.

Technological Advancements and Miniaturization

Japan is the global leader in innovation and technological advancement, and the market is thus driven by it. On-going research and development (R&D) efforts ensure that smaller, more efficient, and cost-effective biochips are being designed, thereby increasing their usage manifold. Nanotechnology and microfluidics, among miniaturization technologies, opened up the lab-on-a-chip (LOC) systems with the integration of multiple laboratory functions into a single microchip. These developments can be easily used in point-of-care testing, environmental monitoring, and even wearable healthcare devices. Another revolutionary trend is the use of AI with biochips. AI algorithms combined with biochips advanced data analyses capabilities, allowing faster and accurate interpretation of biological data. According to the IMARC Group, the Japan AI market is projected to hit US$ 8,777 million by 2033.

Strong R&D Support and Favorable Government Initiatives

Funding by Japan's government in support of the development of biochip, tax incentives, and public-private partnerships all ensure the country supports biochips. Strong support for this has allowed the nation to become very vibrant for the carrying out of biotechnology research and innovation on biochips. The government has placed targets for the development of precision medicine and advanced diagnostics through which biochips would be applied. In 2024, the Japanese government is investing in developing a green healthcare system. This major step shows Japan is determined to address the health consequences of climate change and will ensure a sustainable and resilient health structure. This is further facilitating efficient chip development. Private sector participants also are actively investing in R&D. Companies are announcing their strategy to partner with universities to develop biochip platforms for neurological disease research, utilising AI to decode the intricate proteomic data. These collaborations underscore the robust interplay of academia, industry, and government collaboration towards developing biochip technology. With a strong research environment and government initiatives pushing innovations forward, the country becomes an attractive hub for domestic and international stakeholders.

Japan Biochips Industry Segmentation:

Analysis by Product Type:

DNA Chip
Protein Chip
Lab-On-a-Chip
Enzyme Chip

The DNA chip market segment is one of the major segments in the Japanese biochips market, with strong applications in genomics, gene expression analysis, and personalized medicine. DNA chips or DNA microarrays are primarily applied for the detection of genetic mutations, gene expression pattern analysis, and identification of biomarkers for diseases such as cancer and rare genetic disorders. These chips are vital in the fast-evolving field of precision medicine, where treatment strategies are based on the understanding of an individual's genetic profile.

The protein chip segment is gaining momentum in Japan due to its applications in proteomics, disease diagnostics, and drug discovery. Protein chips are used to analyze protein-protein interactions, identify disease biomarkers, and study immune responses. This segment has been particularly important in the study of infectious diseases and autoimmune disorders.

LOC devices are one of the fastest-growing areas in the biochips market in Japan due to their versatility and portability. LOC devices are multiple laboratory functions integrated onto a single microchip, allowing rapid and cost-effective biochemical analyses. LOC chips are widely used in point-of-care diagnostics, environmental monitoring, and food safety testing.

The niche but ever-growing importance of the enzyme chip segment in Japan's biochips market is particularly within enzymatic activity analysis and biosensing applications. These chips are used in industries such as healthcare, environmental monitoring, and industrial biotechnology, to study enzyme-substrate interactions, detect specific metabolites, and monitor biochemical processes.

Analysis by Fabrication Technique:

Microarray
Microfluidic

The microarray fabrication technique segment is a fundamental part of the biochips market in Japan, which is mainly attributed to the applications in high-throughput genomics and proteomics research. Microarrays are used in gene expression profiling, biomarker discovery, and drug development; thousands of genetic or protein interactions can be analyzed at the same time.

The microfluidic fabrication technique is growing with great speed in Japan with its integration into lab-on-a-chip (LOC) devices and the ability of doing complex biological and chemical analyses without needing large sample volumes. In POC diagnostics, personalized healthcare, and environmental monitoring, microfluidic biochips are widely being applied because of their portability, speed, and economy.

Analysis by Analysis Method:

Electrophoresis
Luminescence
Mass Spectrometry
Electrical Signals
Magnetism

The electrophoresis analysis method segment plays a crucial role in the Japan biochips market because of its exceptional precision in separating and examining biomolecules like DNA, RNA, and proteins. This approach is widely utilized in genomics, proteomics, and clinical diagnostics, especially for purposes such as gene expression analysis and the detection of disease biomarkers.

The luminescence-based analysis method is one of the emerging segments in the Japan biochips market, as it has a high sensitivity for detecting biomolecular interactions. This technique is highly used in assays for enzyme activity, drug screening, and immunological testing. Luminescence biochips are best for producing real-time, quantifiable results, making them very suitable for diagnostic applications.

The mass spectrometry analysis method segment is gaining traction in Japan because no other method can provide the matchless precision in molecular identification and quantification. Proteomics, metabolomics, and pharmaceutical research are witnessing the increasing use of biochips integrated with mass spectrometry, which enable the discovery of biomarkers and drug targets.

The electrical signals analysis method segment has emerged as a critical area of growth in the Japan biochips market, leveraging biochips' ability to detect and quantify electrical changes caused by biological interactions. These biochips are particularly effective for biosensing applications, such as glucose monitoring, neural activity studies, and cardiac biomarker detection.

The magnetism-based analysis method segment is an emerging area in the Japan biochips market, primarily used for detecting magnetic particles conjugated with biomolecules such as proteins, DNA, and cells. This method offers a unique advantage in its ability to perform label-free and non-invasive biomolecular analysis.

Analysis by Application:

Molecular Analysis
- Hybridization
- Protein
- Immunological
- Biomolecules
- Biomarker
- Others
Diagnosis
- Gene Diagnosis
- Oncology
- Inflammatory
- Others
Non-Biological Usage

The molecular analysis (hybridization, protein, immunological, biomolecules, biomarker, and others) segment is a foundational application area within the Japan biochips market, largely driven by advancements in genomics, proteomics, and biomolecular research. Biochips in this segment are used for analyzing genetic material, studying protein interactions, and detecting biomarkers for various diseases. Applications such as DNA hybridization, protein profiling, and immunological assays are particularly prominent, supporting critical research in fields like oncology, infectious disease, and neurobiology.

The diagnosis (gene diagnosis, oncology, inflammatory, and others) segment accounts for a significant share of the biochips market in Japan, driven by the need for early and accurate disease detection. Biochips are widely employed for applications such as gene diagnosis, oncology testing, and identifying inflammatory diseases.

The non-biological usage segment is an emerging application area in the Japan biochips market, expanding beyond healthcare into fields such as environmental monitoring, food safety, and forensics. Biochips in this category are used to detect contaminants, monitor air and water quality, and ensure the safety of food products.

Analysis by End User:

Pharmaceutical and Biotechnology Companies
Hospitals and Diagnostics Centers
Academic and Research Institutes
Others

Pharmaceutical and biotechnology companies represent a major end-user segment in the market, driven by the technology's ability to streamline drug discovery, development, and quality control processes. Biochips are widely used for high-throughput screening of drug candidates, identifying potential drug targets, and analyzing biomolecular interactions, which significantly reduce development timelines and costs.

Hospitals and diagnostic centers constitute a rapidly growing end-user segment for biochips, driven by the rising demand for advanced diagnostic solutions in Japan's healthcare system. Biochips are widely used in clinical diagnostics for early disease detection, particularly in oncology, genetic disorders, and infectious diseases. The segment witnessed significant growth in 2024, with hospitals integrating biochip-based platforms for real-time diagnostics and personalized treatment planning.

Academic and research institutes are pivotal end users of biochips in Japan, leveraging the technology for fundamental and applied research across genomics, proteomics, and molecular biology. Biochips are integral tools for studying gene expression, protein interactions, and disease mechanisms, aiding in breakthroughs in areas such as regenerative medicine and cancer research.

Competitive Landscape:

One of the most critical approaches for market players is their significant focus on R&D to develop advanced biochip technologies that cater to diverse applications such as precision medicine, drug discovery, and diagnostics. Japan's leadership in innovation is supported by its government initiatives, which encourage private companies to push the boundaries of biotechnology. Frequent product launches with cutting-edge features have been a key strategy for players in the Japan biochips market. By introducing innovative biochip platforms, companies are not only addressing growing consumer demands but also creating new opportunities in emerging fields like precision agriculture, food safety, and wearable healthcare. Collaborations and partnerships between industry players, academic institutions, and research organizations have become an essential strategy for driving innovation and commercialization in the biochips market. In Japan, public-private partnerships are particularly strong, supported by government programs that encourage cooperation to advance biotechnology.

The report provides a comprehensive analysis of the competitive landscape in the Japan biochips market with detailed profiles of all major companies.

Key Questions Answered in This Report

1. What are biochips?
2. How big is the Japan biochips market?
3. What is the expected growth rate of the Japan biochips market during 2025-2033?
4. What are the key factors driving the Japan biochips market?
5. What are the key regions in the Japan biochips market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biochips Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Biochips Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Biochips Market - Breakup by Product Type

6.1 DNA Chip
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Protein Chip
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Lab-On-a-Chip
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Enzyme Chip
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)

7 Japan Biochips Market - Breakup by Fabrication Technique

7.1 Microarray
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Microfluidic
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)

8 Japan Biochips Market - Breakup by Analysis Method

8.1 Electrophoresis
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Luminescence
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Mass Spectrometry
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Electrical Signals
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)
8.5 Magnetism
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2019-2024)
- 8.5.3 Market Forecast (2025-2033)

9 Japan Biochips Market - Breakup by Application

9.1 Molecular Analysis
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Segmentation
  - 9.1.3.1 Hybridization
  - 9.1.3.2 Protein
  - 9.1.3.3 Immunological
  - 9.1.3.4 Biomolecules
  - 9.1.3.5 Biomarker
  - 9.1.3.6 Others
- 9.1.4 Market Forecast (2025-2033)
9.2 Diagnosis
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Segmentation
  - 9.2.3.1 Gene Diagnosis
  - 9.2.3.2 Oncology
  - 9.2.3.3 Inflammatory
  - 9.2.3.4 Others
- 9.2.4 Market Forecast (2025-2033)
9.3 Non-Biological Usage
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)

10 Japan Biochips Market - Breakup by End User

10.1 Pharmaceutical and Biotechnology Companies
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2019-2024)
- 10.1.3 Market Forecast (2025-2033)
10.2 Hospitals and Diagnostics Centers
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2019-2024)
- 10.2.3 Market Forecast (2025-2033)
10.3 Academic and Research Institutes
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2019-2024)
- 10.3.3 Market Forecast (2025-2033)
10.4 Others
- 10.4.1 Historical and Current Market Trends (2019-2024)
- 10.4.2 Market Forecast (2025-2033)

11 Japan Biochips Market - Competitive Landscape

11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant

12 Profiles of Key Players

12.1 Company A
- 12.1.1 Business Overview
- 12.1.2 Product Portfolio
- 12.1.3 Business Strategies
- 12.1.4 SWOT Analysis
- 12.1.5 Major News and Events
12.2 Company B
- 12.2.1 Business Overview
- 12.2.2 Product Portfolio
- 12.2.3 Business Strategies
- 12.2.4 SWOT Analysis
- 12.2.5 Major News and Events
12.3 Company C
- 12.3.1 Business Overview
- 12.3.2 Product Portfolio
- 12.3.3 Business Strategies
- 12.3.4 SWOT Analysis
- 12.3.5 Major News and Events
12.4 Company D
- 12.4.1 Business Overview
- 12.4.2 Product Portfolio
- 12.4.3 Business Strategies
- 12.4.4 SWOT Analysis
- 12.4.5 Major News and Events
12.5 Company E
- 12.5.1 Business Overview
- 12.5.2 Product Portfolio
- 12.5.3 Business Strategies
- 12.5.4 SWOT Analysis
- 12.5.5 Major News and Events

13 Japan Biochips Market - Industry Analysis

13.1 Drivers, Restraints, and Opportunities
- 13.1.1 Overview
- 13.1.2 Drivers
- 13.1.3 Restraints
- 13.1.4 Opportunities
13.2 Porters Five Forces Analysis
- 13.2.1 Overview
- 13.2.2 Bargaining Power of Buyers
- 13.2.3 Bargaining Power of Suppliers
- 13.2.4 Degree of Competition
- 13.2.5 Threat of New Entrants
- 13.2.6 Threat of Substitutes
13.3 Value Chain Analysis

14 Appendix

02-2729-4219

+886-2-2729-4219

License/价格

日本生物晶片市场规模、份额、趋势及预测（按产品类型、製造技术、分析方法、应用、最终用户和地区），2025 年至 2033 年

Japan Biochips Market Size, Share, Trends and Forecast by Product Type, Fabrication Technique, Analysis Method, Application, End User, and Region, 2025-2033

日本生物晶片市场趋势：

目录

第一章：前言

第二章：范围与方法

第三章：执行摘要

第四章：日本生物晶片市场－简介

第五章：日本生物晶片市场格局

第六章：日本生物晶片市场-细分：依产品类型

第七章：日本生物晶片市场-细分：依製造技术

第 8 章：日本生物晶片市场 - 细分：按分析方法

第九章：日本生物晶片市场-细分：依应用

第十章：日本生物晶片市场-细分：依最终用户

第 11 章：日本生物晶片市场-竞争格局

第 12 章：关键参与者简介

第十三章：日本生物晶片市场-产业分析

第 14 章：附录